Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus

Xiaomin Zhang,Chang Liu,Jieli Yang,Hefei Ren,Jiafeng Zhang,Sai Chen,Jigang Ren,Lin Zhou
DOI: https://doi.org/10.1016/j.intimp.2022.109155
IF: 5.714
2022-10-01
International Immunopharmacology
Abstract:BackgroundSystemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple system functions. Our study aimed to screen out more effective new indicators that can assist clinical diagnosis and judge disease activity.MethodsWe first screened serum levels of 45 cytokines of SLE patients (n = 3) and healthy controls (n = 3). Subsequently, we selected five elevated cytokines for verification with an expanded sample size. Then, the relationship between cytokines and laboratory parameters was also investigated. Finally, we used receiver operating characteristic (ROC) curves to assess the clinical value of these cytokines.ResultsThrough screening of 45 cytokines, 15 were found to be elevated in SLE patients. We chose five cytokines (IL-6, IL-10, IL-1RA, IP-10 and LIF) for further research and found elevated expression of all five cytokines in SLE patients. Serum levels of IL-10, IL-1RA and LIF were positively correlated with SLEDAI-2K score. Besides, the level of IL-10 was significantly positively correlated with serum IgG and erythrocyte sedimentation rate (ESR); IL-1RA was significantly negatively correlated with C3 and C4; and LIF was significantly positively correlated with serum IgG, C-reactive protein (CRP), and ESR. Furthermore, IL-1RA and LIF were strongly positively correlated with 24-hour urine protein levels. The ROC analysis showed that IL-1RA has good diagnostic value, and IL-10 and LIF levels can be utilized to discriminate between active and inactive SLE.ConclusionIL-1RA can be used as a biomarker for diagnosing SLE, while IL-10 and LIF can be indicators to discriminate between active and inactive SLE.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?